Two medicines, side by side
Loteprednol vs prednisolone
Loteprednol is labeled for pain; prednisolone for anemia, leukemia, lymphoma and myeloma and multiple sclerosis. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of loteprednol since 1998 and of prednisolone since 1955. Pharmacies paid $10.47 per mL (Loteprednol etabonate 0.5% drp) and $4.72 per mL (Prednisolone ac 1% eye drop) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Prednisolone's other strengths are brand-only: $30.66 per mL (Pred mild 0.12% eye drops).
Check it at the source: the loteprednol FDA label on DailyMed (effective February 7, 2026); the prednisolone FDA label on DailyMed (effective June 25, 2026).
Highlights of the loteprednol record
Loteprednol (Lotemax) · label of February 7, 2026
Used for
From the label: indicationsLoteprednol Etabonate Ophthalmic Suspension, 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
On the market
- Earliest approval on file
- March 9, 1998
- Generic labelers
- 8 labelers
- Pharmacy cost
- $10.47 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the prednisolone record
Prednisolone (Pred) · label of June 25, 2026
Used for
From the label: indicationsPrednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. […]
On the market
- Earliest approval on file
- May 22, 1955
- Generic labelers
- 25 labelers
- Pharmacy cost
- $4.72 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 9
Source: FDA drug labels via openFDA (Loteprednol label of February 7, 2026, Prednisolone label of June 25, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do loteprednol and prednisolone differ on the record?
Both are in FDA's class corticosteroids.
Generics: loteprednol since 2019; prednisolone since 1971 (Drugs@FDA).
| Loteprednol | Prednisolone | |
|---|---|---|
| Labeled for | Pain | Anemia, Leukemia, lymphoma and myeloma, Multiple sclerosis, Osteoarthritis, Asthma, Allergies, Herpes and shingles, Crohn's disease and ulcerative colitis, Eczema (atopic dermatitis), Organ transplant rejection |
| Pharmacologic class | Corticosteroid | Corticosteroid |
| How it works (label) | n/a | n/a |
| Half-life (label) | n/a | Prednisolone is 70-90% protein-bound in the plasma and it is eliminated from the plasma with a half-life of 2 to 4 hours. |
| Earliest approval on file (Drugs@FDA) | March 9, 1998 | May 22, 1955 |
| First generic approved | April 17, 2019 | November 24, 1971 |
| Generic labelers (NDC) | 8 labelers | 25 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $10.47 per mL (Loteprednol etabonate 0.5% drp) | $4.72 per mL (Prednisolone ac 1% eye drop) |
| 12-month price change | -46% | +4% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 9 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 5,309 | 191,407 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to loteprednol
- every medicine labeled for the same conditions